Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial

被引：0
|
作者：
Franco Maggiolo
Giuliano Rizzardini
Jean-Michel Molina
Federico Pulido
Stephane De Wit
Linos Vandekerckhove
Juan Berenguer
Michelle L. D’Antoni
Christiana Blair
Susan K. Chuck
David Piontkowsky
Hal Martin
Richard Haubrich
Ian R. McNicholl
Joel Gallant
机构：
[1] ASST Papa Giovanni XXIII,Division of Infectious Diseases
[2] Luigi Sacco Hospital,Division of Infectious Diseases
[3] ASST Fatebenefratelli Sacco,School of Clinical Medicine, Faculty of Health Science
[4] University of the Witwatersrand,Department of Infectious Diseases
[5] Saint Louis Hospital,Infectious Diseases
[6] University Paris Diderot,undefined
[7] Unidad VIH,undefined
[8] Hospital Universitario 12 de Octubre,undefined
[9] imas12,undefined
[10] UCM,undefined
[11] St Pierre University Hospital,undefined
[12] Université Libre de Bruxelles,undefined
[13] University Hospital Ghent,undefined
[14] Hospital General Universitario Gregorio Marañón (IiSGM),undefined
[15] Gilead Sciences,undefined
来源：
Infectious Diseases and Therapy | 2021年 / 10卷
关键词：
Age; Bictegravir; Clinical trial; Emtricitabine; HIV; Older; Safety; Tenofovir alafenamide;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：775 / 788
页数：13
相关论文
共 50 条
  • [1] Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial
    Maggiolo, Franco
    Rizzardini, Giuliano
    Molina, Jean-Michel
    Pulido, Federico
    De Wit, Stephane
    Vandekerckhove, Linos
    Berenguer, Juan
    D'Antoni, Michelle L.
    Blair, Christiana
    Chuck, Susan K.
    Piontkowsky, David
    Martin, Hal
    Haubrich, Richard
    McNicholl, Ian R.
    Gallant, Joel
    INFECTIOUS DISEASES AND THERAPY, 2021, 10 (02) : 775 - 788
  • [2] Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV: Results of a 96-week, phase 3b, open-label, switch trial in virologically suppressed people ≥65 years of age
    Maggiolo, Franco
    Rizzardini, Giuliano
    Molina, Jean-Michel
    Pulido, Federico
    De Wit, Stephane
    Vandekerckhove, Linos
    Berenguer, Juan
    D'Antoni, Michelle L.
    Blair, Christiana
    Chuck, Susan K.
    Piontkowsky, David
    Martin, Hal
    Haubrich, Richard
    McNicholl, Ian R.
    Gallant, Joel
    HIV MEDICINE, 2023, 24 (01) : 27 - 36
  • [3] Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study
    Hagins, Debbie
    Kumar, Princy
    Saag, Michael
    Wurapa, Anson K.
    Brar, Indira
    Berger, Daniel
    Osiyemi, Olayemi
    Hileman, Corrilynn O.
    Ramgopal, Moti N.
    McDonald, Cheryl
    Blair, Christiana
    Andreatta, Kristen
    Collins, Sean E.
    Brainard, Diana M.
    Martin, Hal
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2021, 88 (01) : 86 - 95
  • [4] Week 96 Results of Bictegravir/Emtricitabine/Tenofovir Alafenamide for HIV Treatment in People With Substance Use Disorders
    Havens, Joshua P.
    Bares, Sara H.
    Lyden, Elizabeth
    Fadul, Nada
    Swindells, Susan
    OPEN FORUM INFECTIOUS DISEASES, 2025, 12 (01):
  • [5] Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial
    Kityo, Cissy
    Hagins, Debbie
    Koenig, Ellen
    Avihingsanon, Anchalee
    Chetchotisakd, Ploenchan
    Supparatpinyo, Khuanchai
    Gankina, Natalya
    Pokrovsky, Vadim
    Voronin, Evgeny
    Stephens, Jeffrey L.
    DeJesus, Edwin
    Wang, Hui
    Acosta, Rima K.
    Cao, Huyen
    Quirk, Erin
    Martin, Hal
    Makadzange, Tariro
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2019, 82 (03) : 321 - 328
  • [6] Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial
    Maggiolo, Franco
    Rizzardini, Giuliano
    Raffi, Francois
    Pulido, Federico
    Gracia Mateo-Garcia, Maria
    Molina, Jean-Michel
    Ong, Edmund
    Shao, Yongwu
    Piontkowsky, David
    Das, Moupali
    McNicholl, Ian
    Haubrich, Richard
    LANCET HIV, 2019, 6 (10): : E655 - E666
  • [7] Real-life data of immune recovery using bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people living with HIV. Results at 48-96 weeks of RETROBIC Study
    Troya, Jesus
    Pousada, Guillermo
    Mican, Rafael
    Galera, Carlos
    Sanz, Jose
    de los Santos, Ignacio
    Duenas, Carlos
    Cabello, Noemi
    Martin, Cristina
    Galindo, Maria Josefa
    Garcinuno, Maria Angeles
    Pedrero-Tome, Roberto
    Buzon, Luis
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2024, 79 (03) : 595 - 607
  • [8] Switching to tenofovir alafenamide in patients with virologically suppressed chronic hepatitis B and renal or hepatic impairment: final week 96 results from an open-label, multicentre, phase 2 study
    Janssen, Harry L. A.
    Lim, Young-Suk
    Lampertico, Pietro
    Heo, Jeong
    Chen, Chi-Yi
    Fournier, Claire
    Tsang, Tak Yin Owen
    Bae, Ho
    Chen, Chien-Hung
    Coffin, Carla S.
    Ahn, Sang Hoon
    Trinh, Huy
    Flaherty, John F.
    Abramov, Frida
    Zhao, Yang
    Liu, Yang
    Lau, Audrey
    German, Polina
    Chuang, Wan-Long
    Agarwal, Kosh
    Gane, Edward
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2024, 9 (08): : 718 - 733
  • [9] Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study
    Pozniak, Anton
    Arribas, Jose R.
    Gathe, Joseph
    Gupta, Samir K.
    Post, Frank A.
    Bloch, Mark
    Avihingsanon, Anchalee
    Crofoot, Gordon
    Benson, Paul
    Lichtenstein, Kenneth
    Ramgopal, Moti
    Chetchotisakd, Ploenchan
    Custodio, Joseph M.
    Abram, Michael E.
    Wei, Xuelian
    Cheng, Andrew
    McCallister, Scott
    SenGupta, Devi
    Fordyce, Marshall W.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2016, 71 (05) : 530 - 537
  • [10] Outcomes of switching from protease inhibitor-based antiretroviral therapy to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically suppressed adults with nucleos(t)ide analogue resistance- a phase IV randomised, open-label study (PIBIK study)
    Iwuji, Collins
    Waters, Laura
    Milinkovic, Ana
    Orkin, Chloe
    Fox, Julie
    Post, Frank
    Perry, Nicky
    Bruce, Chloe
    Dailey, Natalie
    To, Ye
    Bremner, Stephen
    Churchill, Duncan
    Geretti, Anna Maria
    VIROLOGY JOURNAL, 2025, 22 (01)
12345